Mechanistically, resistance to drugs targeting PD-1/PD-L1 can be due to the following aspects: 1) lack of tumor immunogenicity, 2) T cell dysfunction, 3) abnormal expression of PD-L1. The gene discussed is CD274; the disease is neoplasm.